News

'Decision aids' inform men but don’t alter prostate screening rate


 

FROM JAMA INTERNAL MEDICINE

It remains critical to assist men in making informed decisions regarding screening for prostate cancer, because of the conflicting recommendations for screening and the mixed messages about its effectiveness, they added.

This study was supported by the National Cancer Institute, the Department of Defense, and the Lombardi Comprehensive Cancer Center. No financial conflicts of interest were reported.

Pages

Recommended Reading

Androgen deprivation therapy linked to acute kidney injury
MDedge Hematology and Oncology
High-risk smokers benefit most from CT screening for lung cancer
MDedge Hematology and Oncology
Cancer survivors may have lower Alzheimer’s risk
MDedge Hematology and Oncology
Radium-223 prolongs survival in metastatic prostate cancer
MDedge Hematology and Oncology
Khorana score tracks risk of cancer death
MDedge Hematology and Oncology
No increased cancer risk in children born after assisted conception
MDedge Hematology and Oncology
Racial disparities found in thyroid cancer care
MDedge Hematology and Oncology
Racial discrepancy in breast cancer survival examined
MDedge Hematology and Oncology
Stem cell mutations in breast cancer may confer metastatic risk
MDedge Hematology and Oncology
Guidelines issued on radiation-induced heart disease
MDedge Hematology and Oncology